Results 161 to 170 of about 35,267 (219)

Conference Report on the 2025 Annual Review of the Essential Programme on Immunization in DR Congo: Dealing with Complexity. [PDF]

Vaccines (Basel)
Mulumba A, Mboussou F, Nasaka P, Byamwitenga AM, Cikomola A, Nogier C, Gaha TN, Mwika M, Nguimbis BT, Farham B, Ancia A, Impouma B.   +11 more
europepmc   +1 more source

The impact of social vulnerability on primary vaccine coverage in children with sickle cell disease. [PDF]

Front Public Health
Shi JS, LaFon E, Sutaria A, Attell BK, Zhou M, Tang A, Snyder AB.   +6 more
europepmc   +1 more source

Shotgun metagenomic profiling of bacterial microbiomes, metagenome-assembled genomes and antimicrobial resistance in respiratory and blood samples from Gambian children with pneumonia

Khan D, Espinoza JL, Tientcheu P, Otchere ID, Mohammed NI, Worwui A, Nicol MP, Kwambana-Adams B, Antonio M, Dupont CL.   +9 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Haemophilus parasuis vaccines

Veterinary Immunology and Immunopathology, 2016
Glässer's disease, which is caused by Haemophilus parasuis, is a major threat to swine throughout the world. At present, the predominant method of controlling this disease is through vaccination with an inactivated vaccine, which has many limitations. For example, there is no available method to differentiate between infected and vaccinated animals. In
Huisheng Liu, Qiao Xue, Qiaoying Zeng, Zhanqin Zhao   +3 more
openaire   +2 more sources

Haemophilus b Polysaccharide Vaccine

JAMA: The Journal of the American Medical Association, 1989
• The antibody response to polysaccharide vaccines is well known to be age variable, with younger infants or children responding less dependably and with lower antibody levels. The fate of these induced antibodies over time is less well understood. We studied the antibody kinetics of β-Capsa 1, a Haemophilus B polysaccharide vaccine, in 185 children ...
F B, Coles, A R, Stacy
  +5 more sources

Haemophilus b Disease After Vaccination With Haemophilus b Polysaccharide or Conjugate Vaccine

Archives of Pediatrics & Adolescent Medicine, 1991
The reported frequency of invasive Haemophilus influenzae type b disease occurring within 1 year after immunization was compared in American children who received either Praxis Biologics' Haemophilus b polysaccharide vaccine or Connaught Laboratories' Haemophilus b conjugate vaccine during the first year of distribution.
C E, Frasch, E E, Hiner, T P, Gross
openaire   +2 more sources

Decreased Haemophilus colonization in children vaccinated with Haemophilus influenzae type b conjugate vaccine

The Journal of Pediatrics, 1993
The incidence of invasive Haemophilus disease has unexpectedly decreased in unvaccinated children since the introduction of conjugate vaccine in the United States. The purpose of this study was to determine whether conjugate vaccination decreases colonization with Haemophilus influenzae type b.This study was a prospective, bimonthly survey of ...
T V, Murphy, P, Pastor, F, Medley, M T, Osterholm, D M, Granoff   +4 more
openaire   +2 more sources

Haemophilus influenzae Vaccine

Pediatrics, 1986
The primary advice from both the Committee on Infectious Diseases of the American Academy of Pediatrics1 and the Immunization Practices Advisory Committee2 is to recommend that a newly licensed vaccine against Haemophilus influenzae type b should be given to all children at 24 months of age.
openaire   +2 more sources

Vaccin anti-Haemophilus influenzae

Médecine et Maladies Infectieuses, 1989
Resume L'Haemophilus influenzae de type B est responsable de la majorite des meningites purulentes de l'enfant avant 5 ans, de toutes les epiglottites, d'un nombre important de septicemies, de cellulites, de pneumopathies et de 10 % des otites a Haemophilus.
Ph. Reinert, L. Hessel, B. Palestro, M. Amzallag, M. Cadoz   +4 more
openaire   +1 more source